Prof Giuseppe Curigliano talks to ecancer about the heterogeneity of tumours and the challenges of biomarker development at IMPAKT 2012 in Brussels, May 2012.

Specific mutations like PI3K mutation or p54 mutation provide targetable mutations for drug development; however, mutations found in the primary tumour are not the same as the metastatic tumour.

Once a tumour is present, significant changes occur in the body and to the immune system when the tumour metastases treatment needs to focus on the microenvironment. Research conducted on future treatments involves CTCs, bone cells and tools to quickly characterise tumours.

Filming Supported by Amgen